MENU
APR 23, 2018 8:00 AM PDT

UFH monitoring focusing on use of anti-Xa for critically ill and general patient management

Sponsored by: Diagnostica Stago, Inc.
Speaker
  • Professor of Anesthesiology, Professor of Surgery (Cardiothoracic), CoDirector, Cardiothoracic ICU, Duke University Hospital
    Biography
      Dr. Jerrold Levy is Professor of Anesthesiology and Surgery (Cardiothoracic) and Co-director of the Cardiothoracic Surgical Intensive Care Unit at Duke University Medical Center. He obtained his medical degree from the University of Miami, and undertook his residency and fellowships at the Massachusetts General Hospital and Harvard Medical School, Boston. His clinical and research interests include therapeutic strategies to prevent and treat bleeding; anticoagulation and its reversal, clinical applications of recombinant and purified protein concentrates, therapeutic approaches to shock/ventricular dysfunction, and anaphylaxis.

    Abstract

    Despite the development of new anticoagulants, unfractionated heparin (UFH) continues to be a primary choice for intravenous anticoagulant therapy because of its titratability, short half-life, ability to use in patients with renal failure, and acute reversibility. UFH continues to be the mainstay of parenteral anticoagulation especially in critically ill patients and to maintain anticoagulation during mechanical cardiopulmonary support.  As with all intravenous anticoagulants, monitoring is required for its use. In critically ill patients, UFH can be monitored by multiple tests that include the activated partial thromboplastin time (aPTT), heparin activity measured by antifactor Xa (anti-Xa), or activated clotting time (ACT). Although the aPTT and the ACT are frequently used for monitoring, there are multiple limitations. Anti-Xa heparin monitoring represents an important alternative, and I routinely used anti-Xa monitoring as our standard of measurement in my previous institution. However, aPTT is the standard for monitoring in my current institution.  Despite this, I frequently use anti-Xa monitoring as an important guide to therapy especially in critically ill, complex patients especially during ECMO and mechanical cardiopulmonary support. Anti-Xa monitoring is a more direct measure of UFH activity than the aPTT, demonstrates less variability and is most helpful when conflicting values occur during aPTT monitoring.  In this presentation, I will review UFH monitoring focusing on the use of the anti-Xa for critically ill and general patient management.

    Learning Objectives

    • Summarize different methods for heparin monitoring in the ICU and hospital
    • Describe limitations and benefits of different testing focusing on anti-Xa monitoring
    • Discuss the role of anti-Xa monitoring and clinical applications in critically ill patients

     

     P.A.C.E. ® Credits are no longer available for this webinar.


    Show Resources
    APR 23, 2018 8:00 AM PDT

    UFH monitoring focusing on use of anti-Xa for critically ill and general patient management

    Sponsored by: Diagnostica Stago, Inc.

    Specialty

    Laboratory Testing

    Hematology

    Clinical Chemistry

    Clinical Diagnostics

    Immunology

    Microbiology

    Infectious Disease

    Biochemistry

    Molecular Diagnostics

    Molecular Biology

    Antibodies

    Biotechnology

    Chemistry

    Diagnostics

    Cancer Research

    Geography

    North America80%

    Asia9%

    Europe6%

    South America2%

    Africa1%

    Registration Source

    Website Visitors63%

    Email Promotions21%

    WAVE Newsletter Promotion12%

    Website Banners2%

    Social Media Promotions2%

    Job Title

    Medical Laboratory Technician27%

    Clinical Laboratory Scientist22%

    Lab Management14%

    Medical Doctor/Specialist9%

    Facility/Department Manager8%

    Student6%

    Executive4%

    Educator/Faculty3%

    Research Scientist2%

    QC/QA2%

    Consultant1%

    Scientist1%

    Pharmacist1%

    Biologist1%

    Organization

    Hospital48%

    Clinical Laboratory16%

    Academic Institution6%

    Medical Center5%

    Ambulatory Care3%

    Government3%

    Biotech Company2%

    Research Institute2%

    Medical Device Company1%

    Industrial Company1%

    Medical School1%

    Pharmaceutical Company1%

    Non-Profit Organization1%

    Manufacturer - Other1%

    Other4%


    Show Resources
    Show Resources
    Attendees
    • See more